Worldwide Clinical Trials acquisition marks a significant expansion in the global contract research organization (CRO) landscape. Worldwide Clinical Trials has officially completed its acquisition of Catalyst Clinical Research, a specialized oncology CRO and scalable functional service provider (FSP).
This strategic move strengthens Worldwide’s oncology, biometrics, and FSP capabilities. As a result, the combined organization now supports approximately 4,400 employees across more than 70 countries. The acquisition enhances Worldwide’s global reach and broadens its service offerings for biopharma customers.
Strengthening Oncology and Early-Phase Expertise
The Worldwide Clinical Trials acquisition significantly expands early-phase oncology expertise. Catalyst brings deep scientific knowledge and a robust FSP model. Consequently, Worldwide strengthens its therapeutic capabilities across neuroscience, oncology, rare diseases, and internal medicine.
Clients now benefit from an expanded suite of services and innovative technology platforms. In addition, the broader global site network enables more efficient and flexible clinical development across the entire trial lifecycle.
Alistair Macdonald, CEO of Worldwide, stated that the acquisition builds a stronger and more capable CRO partner. He emphasized that the deal enhances early-phase oncology services, targeted FSP solutions, and biometrics capabilities. Therefore, customers can expect greater speed, transparency, and flexibility.
Expanding Global Reach and Leadership
The Worldwide Clinical Trials acquisition also reinforces leadership and governance. Nik Morton, former President and CEO of Catalyst, joins Worldwide as EVP and Chief Strategy & Transformation Officer. Moreover, Nick Dyer, Catalyst’s Chairman, joins Worldwide’s Board of Directors.
Matt Jennings, Executive Chairman of Worldwide and Senior Operating Partner at Kohlberg, highlighted that Catalyst’s technology and biotech relationships align with Worldwide’s strategy. Together, the organizations aim to build a differentiated, technology-enabled CRO.
Backed by Leading Investment Firms
Worldwide is a portfolio company of Kohlberg, based in Mount Kisco, New York. Before the transaction, Catalyst was backed by QHP Capital, a life sciences and pharma services investor headquartered in Research Triangle Park, North Carolina.
The integration team has already implemented a comprehensive transition plan. As a result, employees, customers, and partners can expect a smooth integration process. The acquisition amount remains undisclosed.
Driving Innovation in Clinical Research
Ultimately, the Worldwide Clinical Trials acquisition positions the combined organization for accelerated innovation and global growth. By integrating oncology expertise, advanced biometrics, and scalable FSP services, Worldwide enhances its ability to support biopharma companies at every development stage.
This acquisition reflects the ongoing consolidation trend in the CRO industry. More importantly, it underscores Worldwide’s commitment to scientific excellence, operational integrity, and customer-focused clinical development solutions.
Read Also: Nucleome Therapeutics Appoints Dr. Michelle Morrow as Chief Scientific Officer
